MediWound Ltd.: updates and filings

MDWDNASDAQBasic materials · Medicinal Chemicals & Botanical Products

Price

$13.59

November 20, 2026Market cap $174M

What Ploutos Investor adds for MediWound

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 11 fiscal years, from 2015
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 5, 2026 latest annual
  • Nov 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 12, 2026Current report (foreign company)
    Form6-K
  • Nov 5, 2026Current report (foreign company)
    Form6-K
  • Aug 28, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 13, 2026Current report (foreign company)
    Form6-K
  • May 27, 2026Current report (foreign company)
    Form6-K
  • May 15, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 6, 2026Current report (foreign company)
    Form6-K
  • Apr 2, 2026Current report (foreign company)
    Form6-K
  • Mar 30, 2026Current report (foreign company)
    Form6-K
  • Mar 5, 2026Shares registered for employees
    FormS-8
  • Mar 5, 2026Annual report (foreign company)for the period to Dec 31, 2025
    Form20-F
  • Mar 5, 2026Current report (foreign company)
    Form6-K
  • Feb 19, 2026Current report (foreign company)
    Form6-K
  • Feb 17, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 11, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 5, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jan 15, 2026Current report (foreign company)
    Form6-K
  • Jan 12, 2026Current report (foreign company)
    Form6-K
  • Nov 20, 2025Current report (foreign company)
    Form6-K
  • Nov 14, 2025Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 12, 2025Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 3, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 23, 2013.

The full analysis

What do MediWound's filings show?

The filings are where every one of MediWound's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.